The Myeloma Institute Treats Multiple Myeloma Patients From All Over the World

Superior clinical outcomes have been achieved at the Myeloma Institute through the "Total Therapy" approach, incorporating upfront tandem transplants. Outcomes have improved through the years with the incorporation of new agents such as thalidomide and bortezomib for consolidation and salvage therapies. Click here for graphs. Click here for a presentation on Treatment Approach at the Myeloma Institute.

MIRT is the only facility in the world that routinely offers Gene Array Analysis for newly referred patients and utilizes this information for patient management and planning of therapy.

*****Myeloma In the News *****

UAMS Performs Record 7,000th Myeloma Stem-Cell Transplant Click here for the story.

Part two: Living with Multiple Myeloma
Click here for the story

Myeloma: Quest for CR May Be Misplaced
Click here for the story

For 10 years, artist Cathy Joyce has been cancer-free. But she still takes life one day a time
Click here for the story

Making progress in treating multiple myeloma with total therapies: issue of complete remission and more
B Barlogie, F van Rhee, J D Shaughnessy Jr, E Anaissie and J Crowley
Leukemia advance online publication, February 28, 2008; doi:10.1038/leu.2008.40
Abstract | Full Text | PDF

An analysis of the clinical and biological significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma | Blood First Edition Paper, prepublished online March 13, 2008; DOI 10.1182/blood-2007-10-119123

Click here for the story

Myeloma Patients Flock to Little Rock
Click here for the story

Click here for the article

Listen to presentations from Myeloma Institute faculty at the June 2007 XIth International Myeloma Workshop:

John Shaughnessy, PhD
Towards a Molecular-Based Risk Stratification of Multiple Myeloma

Joshua Epstein, DSc
The Scid-hu model for Multiple Myeloma

Bart Barlogie, MD, PhD,
Debate II - Should autologous transplant be part of the primary treatment in mm? YES

Our specialized and experienced staff provides
superb medical attention in an atmosphere of friendliness and compassion. Our clinical and basic program is unique in creating rapid application of scientific breakthroughs to treating mutliple
myeloma patients. The quality of the Myeloma Institute's innovative clinical and basic research is known nationally and internationally.

Abstracts

Bortezomib Activates the Immune system to Kill Myeloma Cells. More...

Dr. Frits van Rhee and colleagues published a world first in immunotherapy.  More...

About Multiple Myeloma // About the Myeloma Institute // Becoming a Patient //
Highlights of Our Myeloma Program  // Our Physician Team // Our Nursing Team  //
News/Events/Press Releases // Scientific Publications/Research  // About UAMS
About Little Rock & Arkansas // About The Winthrop P. Rockefeller Cancer Institute //Travel/Directions/Maps //
Contact Us // Make a Donation // Notice of Pricacy Practices

Having problems with the site? E-mail the Webmaster.
Copyright 2002-2005, Myeloma Institute for Research and Therapy, University of Arkansas
for Medical Sciences

Terms and Conditions of Use

The information on the Myeloma Institute web site is not intended as a substitute for professional medical attention. The information is intended only as an aid in understanding current medical knowledge. A physician should always be consulted for any health concern or medical condition. The Myeloma Institute web site provides links to other organizations as a service to our readers. The Myeloma Institute is not responsible for the information provided on other web sites.